Acuta Capital Partners’s Crinetics Pharmaceuticals CRNX Stock Holding History

Acuta Capital Partners’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-122,900	Closed	-$6.28M	–	36
2024 Q4	$6.28M	Sell	122,900 -8,800	-7%	-$492K	6.32%	4
2024 Q3	$6.73M	Sell	131,700 -3,441	-3%	-$177K	5.45%	6
2024 Q2	$6.05M	Buy	135,141 +56,738	+72%	+$2.62M	5.1%	6
2024 Q1	$3.67M	Sell	78,403 -9,097	-10%	-$356K	2.38%	17
2023 Q4	$3.11M	Sell	87,500 -6,500	-7%	-$199K	1.75%	22
2023 Q3	$2.8M	Buy	+94,000	New	+$1.94M	1.87%	19

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acuta Capital Partners's CRNX Position: Q1 2025 in Review

Acuta Capital Partners sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2025, closing a stake of 122,900 shares — an estimated $6.28M sold.

Acuta Capital Partners first reported a position in CRNX in Q3 2023 and held it in 6 quarters. The position peaked at $6.73M in Q3 2024. 227 funds tracked by Wall St. Rank hold CRNX as of Q1 2025.

Acuta Capital Partners reported no remaining Crinetics Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Acuta Capital Partners sold 122,900 Crinetics Pharmaceuticals shares in Q1 2025, an estimated $6.28M.
Acuta Capital Partners first reported a position in Crinetics Pharmaceuticals in Q3 2023 and held it in 6 quarters.
Acuta Capital Partners's Crinetics Pharmaceuticals position peaked at $6.73M in Q3 2024.
227 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2025.

Based on Acuta Capital Partners's 13F filing for Q1 2025, filed 15 May 2025.